POMDOCTOR LIMITED — Form 6-K Summary
Reporting date: October 9, 2026. The filing reports a Nasdaq listing determination and the Company’s intended appeal; it does not provide operating or financial results.
Nasdaq listing status
- Nasdaq notified the Company on October 6, 2026 that its ADS bid price had closed below $1.00 for 30 consecutive business days, from August 24 through October 5, violating Nasdaq Listing Rule 5450(a)(1).
- The Company is ineligible for the usual 180-calendar-day compliance period because it completed a 1-for-18 reverse stock split on June 22, 2026, within the preceding year.
- Nasdaq determined to delist the Company’s securities from the Nasdaq Global Market. Without a timely hearing request, trading suspension would begin at the open on October 15, 2026, followed by Nasdaq’s filing of Form 25-NSE.
Management response, risks, and contingencies
- The Company intends to request a hearing before the Nasdaq Hearings Panel by the October 13, 2026 deadline and present a plan to regain compliance.
- A timely request stays the trading suspension and Form 25-NSE filing while the appeal is pending.
- The Company is evaluating alternatives but cautions that there is no assurance the Panel will grant additional time, the Company will regain or maintain compliance with Nasdaq requirements, or the appeal will succeed.
Financial information and investor verification
The filing provides no revenue, profit, cash flow, margin, debt, liquidity, or financial guidance figures, and no comparison with a prior period.
- Verify whether the Company submitted its hearing request by October 13 and review the Panel’s decision and any resulting compliance conditions.
- Monitor the ADS bid price and the Company’s stated plan to regain compliance.
- Confirm any subsequent Nasdaq trading or listing-status notices.